

chain nodes :
 13 35
 ring nodes :
 1 2 3 4 5 6 7 8 9 10 11 12 15 16 17 18 22 23 24 25 26 27 28 29 30 31
 chain bonds :
 2-13 9-13
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-18 16-17 17-18
 22-23 22-26 23-24 24-25 25-26 27-28 27-31 28-29 29-30 30-31
 exact/norm bonds :
 2-13 9-13 22-23 22-26 23-24 24-25 25-26 27-28 27-31 28-29 29-30 30-31
 exact bonds :
 15-16 15-18 16-17 17-18
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
 isolated ring systems :
 containing 1 : 7 : 15 : 22 : 27 :

G1:[*1], [*2]

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
 12:Atom 13:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 22:Atom 23:CLASS 24:CLASS
 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 35:CLASS 36:Atom

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1841

L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10586954.str



chain nodes :

13 14

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 18 19 20 21

chain bonds :

2-13 9-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 18-19 18-21
19-20 20-21

exact/norm bonds :

2-13 9-13

exact bonds :

18-19 18-21 19-20 20-21

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems :

containing 1 : 7 : 18 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom

Generic attributes :

14:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : 2 or more

Type of Ring System : Monocyclic

Element Count :

Node 14: Limited

C,C3
N,N2
O,O0
S,S0

L3 STRUCTURE uploaded

=> que L3 AND L1 NOT L2

L4 QUE L3 AND L1 NOT L2

=> d 14

L4 HAS NO ANSWERS

L1 SCR 1841

L2 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L3 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.
L4 QUE L3 AND L1 NOT L2

=> s 14 sss sam

SAMPLE SEARCH INITIATED 19:54:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2881 TO ITERATE

69.4% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

24 ANSWERS

FULL FILE PROJECTIONS:	ONLINE	**COMPLETE**	
	BATCH	**COMPLETE**	
PROJECTED ITERATIONS:	54401 TO	60839	
PROJECTED ANSWERS:	339 TO	1043	

L5 24 SEA SSS SAM L3 AND L1 NOT L2

=> =>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1841

L6 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L7 SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10586954 (a).str



```

chain nodes :
13 35
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 15 16 17 18 22 23 24 25 26 27 28
29 30 31
chain bonds :
2-13 9-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 15-16 15-18
16-17 17-18 22-23 22-26 23-24 24-25 25-26 27-28 27-31 28-29 29-30 30-31
exact/norm bonds :

```

2-13 9-13 22-23 22-26 23-24 24-25 25-26 27-28 27-31 28-29 29-30 30-31
exact bonds :
15-16 15-18 16-17 17-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 : 15 : 22 : 27 :

G1:[*1], [*2]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 22:Atom
23:CLASS 24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom
35:CLASS 36:Atom

L8 STRUCTURE UPLOADED

=> que L8 AND L6 NOT L7

L9 QUE L8 AND L6 NOT L7

=> d 19

L9 HAS NO ANSWERS

L6 SCR 1841

L7 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L8 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L9 QUE L8 AND L6 NOT L7

=> s 19 sss sam

SAMPLE SEARCH INITIATED 19:58:59 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 691 TO ITERATE

100.0% PROCESSED 691 ITERATIONS 10 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 12243 TO 15397

PROJECTED ANSWERS: 11 TO 389

L10 10 SEA SSS SAM L8 AND L6 NOT L7

=> => s 19 sss ful

FULL SEARCH INITIATED 19:59:49 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 14956 TO ITERATE

100.0% PROCESSED 14956 ITERATIONS 172 ANSWERS

10/586,954


SEARCH TIME: 00.00.01

L11 172 SEA SSS FUL L8 AND L6 NOT L7


=> => s l11 4 L11
L12

=> d l12 1-4 bib,ab,hitstr


L12 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2008:904002 CAPLUS
 DN 149:298760
 TI Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode
 AU Finlay, M. Raymond V.; Acton, David G.; Andrews, David M.; Barker, Andrew J.; Dennis, Michael; Fisher, Eric; Graham, Mark A.; Green, Clive P.; Heaton, David W.; Karoutchi, Galith; Loddick, Sarah A.; Morgentin, Remy; Roberts, Andrew; Tucker, Julie A.; Weir, Hazel M.
 CS Cancer and Infection Research Area, Cancer and Infection Research Area Alderley Park, Macclesfield, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK
 SO Bioorganic & Medicinal Chemistry Letters (2008), 18(15), 4442-4446
 CODEN: BMCLB8; ISSN: 0960-894X
 PB Elsevier Ltd.
 DT Journal
 LA English
 AB A piperazine series of cyclin-dependent kinase (CDK) inhibitors have been identified. The compds. exhibit excellent physiochem. properties and a novel binding mode, whereby a bridging interaction via a water mol. with Asp 86 of CDK2, leads to selectivity for the CDK family of enzymes over other kinases. Piperazines 2e and 2i (I) were subsequently shown to inhibit tumor growth when dosed orally in a nude mouse xenograft study. Addnl. chemical series that exploit this unexpected interaction with Asp 86 are also described.
 IT 862682-67-5P 862684-49-9P 862771-39-9P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (imidazole piperazines as CDK inhibitors with antitumor activity)
 RN 862682-67-5 CAPLUS
 CN Ethanone, 2-hydroxy-1-[4-[4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl- (CA INDEX NAME)




RN 862684-49-9 CAPLUS
 CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[(4-(4-morpholinyl)phenyl)- (CA INDEX NAME)




RN 862771-39-9 CAPLUS
 CN Ethanone, 1-[4-[4-[(5-fluoro-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-2-hydroxypiperazinyl]-2-hydroxy- (CA INDEX NAME)




IT 862682-69-7P 862682-83-5P 862682-85-7P
 862683-61-2P 862771-37-7P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (imidazole piperazines as CDK inhibitors with antitumor activity)
 RN 862682-69-7 CAPLUS
 CN Ethanone, 2-(dimethylamino)-1-[4-[4-[(4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)



RN 862682-83-5 CAPLUS
 CN 2-Pyrimidinamine, N-[4-[(2-(dimethylamino)ethyl)sulfonyl]-1-piperazinyl]phenyl]-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)- (CA INDEX NAME)




RN 862682-85-7 CAPLUS
 CN 2-Pyrimidinamine, N-[4-[4-[(2-methoxyethyl)sulfonyl]-1-piperazinyl]phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 862683-61-2 CAPLUS
 CN 1-Propanone, 2-hydroxy-1-[4-[(4-(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl)amino]phenyl]-1-piperazinyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 862771-37-7 CAPLUS
 CN Ethanone, 2-(diethylamino)-1-[4-[4-[(4-(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl)amino]phenyl]-1-piperazinyl- (CA INDEX NAME)




IT 862684-45-5 862685-07-2 862685-25-4
862685-40-3

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(imidazole piperazines as CDK inhibitors with antitumor activity)


RN 862684-45-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 862685-07-2 CAPLUS


CN Acetamide, N-[1-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-3-azetidinyl]- (CA INDEX NAME)



RN 862685-25-4 CAPLUS


CN Acetamide, N-[(3R)-1-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862685-40-3 CAPLUS
 CN 2-Pyrrolidinecarboxamide, 1-[4-[(5-fluoro-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)amino]phenyl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.




IT 862682-59-5
 RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
 (imidazole piperazines as CDK inhibitors with antitumor activity)
 RN 862682-59-5 CAPLUS
 CN Ethanone, 1-[4-[(4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino)phenyl]-1-piperazinyl- (CA INDEX NAME)




IT 862682-25-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (imidazole piperazines as CDK inhibitors with antitumor activity)
 RN 862682-25-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-N-[(4-[(methylsulfonyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)



IT 862682-63-1P 862682-81-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (imidazole piperazines as CDK inhibitors with antitumor activity)
 RN 862682-63-1 CAPLUS
 CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 862682-81-3 CAPLUS
 CN 2-Pyrimidinamine, N-[4-[4-(ethenylsulfonyl)-1-piperazinyl]phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:823693 CAPLUS
 DN 143:229875
 TI Preparation of 4-(imidazol-5-yl)-2-anilinopyrimidines as agents for the inhibition of cell proliferation
 IN Andrews, David Michael; Finlay, Maurice Raymond Verschoyle; Green, Clive
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SO PCT Int. Appl., 134 pp.
 CODEN: PIIXXD2

DT Patent
 LA English

Applicant's

FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005075461	A1	20050818	WO 2005-GB303	20050131
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005210248	A1	20050818	AU 2005-210248	20050131
CA 2554076	A1	20050818	CA 2005-2554076	20050131
EP 1748999	A1	20070207	EP 2005-702053	20050131
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1938295	A	20070328	CN 2005-80010057	20050131
BR 2005007351	A	20070703	BR 2005-7351	20050131
JP 2007522145	T	20070809	JP 2006-551902	20050131
US 20070161615	A1	20070712	US 2006-586954	20060725
MX 2006PA08764	A	20061009	MX 2006-PA8764	20060802
IN 2006MN01034	A	20070413	IN 2006-MN1034	20060830
NO 2006003905	A	20061027	NO 2006-3905	20060901
PRAI GB 2004-2277	A	20040203		
GB 2004-11998	A	200404528		
WO 2005-GB303	W	20050131		
OS CASREACT 143:229875; MARPAT 143:229875				
AB Title compds. I [A = N-linked 4-7 membered saturated ring which; R1 = halo, NO2, CN, OH, NH2, etc.; p = 0-4; R2 = halo, NO2, CN, OH, etc.; q = 0-2; R3 = halo, NO2, CN, etc.; n = 0-2; R4 = H, alk(en)ynyl, carbocyclyl, etc.; R5-6 = H, halo, NO2, etc.] are prepared. For instance, 2-[4-(4-(methanesulfonyl)piperazin-1-yl)anilino]-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidine is prepared by the coupling of prior art intermediates 2-Amino-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidine and 1-bromo-4-(4-(methanesulfonyl)piperazinyl)benzene. Example compds. exhibit IC50 in the range of 250 μ M to 1 nM for Cdk2 kinase. I are useful as antiproliferative agents.				
IT 862682-59-5P 862682-63-1P 862682-65-3P				
862682-71-1P 862682-81-3P 862682-89-1P				
862682-91-5P 862682-93-7P 862683-97-4P				
862683-99-6P 862684-33-1P 862684-35-3P				

862684-55-7P 862684-57-9P 862684-59-1P
 862684-63-7P 862684-67-1P 862684-85-3P
 862684-89-7P 862684-97-7P 862684-99-9P
 862685-03-8P 862685-25-4P 862685-27-6P
 862685-29-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 4-(imidazol-5-yl)-2-anilinopyrimidines as agents for inhibition of cyclin dependent kinase and cellular proliferation)


RN 862682-59-5 CAPLUS

CN Ethanone, 1-[4-[4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl- (CA INDEX NAME)




RN 862682-63-1 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 862682-65-3 CAPLUS

CN Ethanone, 2-(acetyloxy)-1-[4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-1-piperazinyl- (CA INDEX NAME)




RN 862682-71-1 CAPLUS

CN Ethanone, 2-chloro-1-[4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-1-piperazinyl- (CA INDEX NAME)




RN 862682-81-3 CAPLUS

CN 2-Pyrimidinamine, N-[4-[4-(ethenylsulfonyl)-1-piperazinyl]phenyl]-4-(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)- (CA INDEX NAME)




RN 862682-89-1 CAPLUS

CN Ethanone, 1-[4-[5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl- (CA INDEX NAME)




RN 862682-91-5 CAPLUS


CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 862682-93-7 CAPLUS
 CN Ethanone, 2-(acetyloxy)-1-[4-[(5-chloro-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)



RN 862683-97-4 CAPLUS
 CN Ethanone, 1-[4-[(5-fluoro-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 862683-99-6 CAPLUS
 CN 2-Pyrimidinamine, 5-fluoro-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-N-(4-(1-piperazinyl)phenyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl


RN 862684-33-1 CAPLUS
 CN Ethanone, 1-[4-[4-[(4-(1-cyclobutyl-2-methyl-1H-imidazol-5-yl)-5-fluoro-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 862684-35-3 CAPLUS
 CN 2-Pyrimidinamine, 4-(1-cyclobutyl-2-methyl-1H-imidazol-5-yl)-5-fluoro-N-(4-(1-piperazinyl)phenyl)- (CA INDEX NAME)




RN 862684-55-7 CAPLUS
 CN Ethanone, 1-[4-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-2-methylphenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 862684-57-9 CAPLUS
 CN Ethanone, 1-[4-[2-chloro-4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl- (CA INDEX NAME)




RN 862684-59-1 CAPLUS
 CN Ethanone, 1-[4-[2-fluoro-4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl- (CA INDEX NAME)



RN 862684-63-7 CAPLUS
 CN Ethanone, 1-[4-[2-chloro-4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl- (CA INDEX NAME)




RN 862684-67-1 CAPLUS
 CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[3-methyl-4-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 862684-85-3 CAPLUS


CN 2-Pyrimidinamine, N-[3-chloro-4-(1-piperazinyl)phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl

RN 862684-89-7 CAPLUS


CN 2-Pyrimidinamine, N-[3-chloro-4-(1-piperazinyl)phenyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 862684-97-7 CAPLUS


CN 3-Azetidinol, 1-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]- (CA INDEX NAME)



RN 862684-99-9 CAPLUS
 CN 3-Azetidinol, 1-[4-[(5-fluoro-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-, 3-methanesulfonate (CA INDEX NAME)




RN 862685-03-8 CAPLUS
 CN 2-Pyrimidinamine, N-[4-(3-amino-1-azetidinyl)phenyl]-5-fluoro-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)- (CA INDEX NAME)



RN 862685-25-4 CAPLUS
 CN Acetamide, N-[(3R)-1-[4-[(5-fluoro-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl)amino]phenyl]-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862685-27-6 CAPLUS

CN Acetamide, N-[(3S)-1-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862685-29-8 CAPLUS

CN 2-Pyrimidinamine, N-[4-[(3R)-3-amino-1-pyrrolidinyl]phenyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 862682-25-5P 862682-27-7P 862682-29-9P

862682-31-3P 862682-33-5P 862682-35-7P

862682-37-9P 862682-39-1P 862682-41-5P

862682-43-7P 862682-45-9P 862682-47-1P

862682-49-3P 862682-51-7P 862682-53-9P

862682-55-1P 862682-57-3P 862682-61-9P

862682-67-5P 862682-69-7P 862682-73-3P

862682-75-5P 862682-77-7P 862682-79-9P

862682-83-5P 862682-85-7P 862682-87-9P

862682-95-9P 862682-97-1P 862682-99-3P

862683-01-0P 862683-03-2P 862683-05-4P

862683-07-6P 862683-09-8P 862683-11-2P

862683-13-4P 862683-15-6P 862683-17-8P


862683-19-0P 862683-21-4P 862683-23-6P
 862683-25-8P 862683-27-0P 862683-29-2P
 862683-31-6P 862683-33-8P 862683-35-0P
 862683-37-2P 862683-39-4P 862683-41-8P
 862683-43-0P 862683-45-2P 862683-47-4P
 862683-49-6P 862683-51-0P 862683-53-2P
 862683-55-4P 862683-57-6P 862683-59-8P
 862683-61-2P 862683-63-4P 862683-65-6P
 862683-67-8P 862683-69-0P 862683-71-4P
 862683-73-6P 862683-75-8P 862683-77-0P
 862683-79-2P 862683-81-6P 862683-83-8P
 862683-85-0P 862683-87-2P 862683-89-4P
 862683-91-8P 862683-93-0P 862683-95-2P
 862684-01-3P 862684-03-5P 862684-05-7P
 862684-07-9P 862684-09-1P 862684-11-5P
 862684-13-7P 862684-15-9P 862684-17-1P
 862684-19-3P 862684-21-7P 862684-23-9P
 862684-25-1P 862684-27-3P 862684-29-5P
 862684-31-9P 862684-37-5P 862684-39-7P
 862684-41-1P 862684-43-3P 862684-45-5P
 862684-49-9P 862684-51-3P 862684-53-5P
 862684-61-5P 862684-65-9P 862684-69-3P
 862684-71-7P 862684-73-9P 862684-75-1P
 862684-77-3P 862684-79-5P 862684-81-9P
 862684-83-1P 862684-87-5P 862684-91-1P
 862684-93-3P 862684-95-5P 862685-05-0P
 862685-07-2P 862685-09-4P 862685-11-8P
 862685-13-0P 862685-15-2P 862685-17-4P
 862685-19-6P 862685-21-0P 862685-23-2P
 862685-31-2P 862685-33-4P 862685-36-7P
 862685-38-9P 862685-40-3P 862685-42-5P
 862685-44-7P 862685-46-9P 862685-48-1P
 862771-40-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of 4-(imidazol-5-yl)-2-anilinopyrimidines as agents for
inhibition of cyclin dependent kinase and cellular proliferation)


RN 862682-25-5 CAPLUS

CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(4-
(methylsulfonyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 862682-27-7 CAPLUS

CN 2-Pyrimidinamine, 5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-
N-[4-(4-(methylsulfonyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 862682-29-9 CAPLUS

CN 2-Pyrimidinamine, 4-(1-(cyclobutyl)-2-methyl-1H-imidazol-5-yl)-N-[4-[4-(methylsulfonyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 862682-31-3 CAPLUS

CN 2-Pyrimidinamine, 4-[1-(cyclopropylmethyl)-2-methyl-1H-imidazol-5-yl]-N-[4-[4-(methylsulfonyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 862682-33-5 CAPLUS


CN 2-Pyrimidinamine, 4-(1,2-diethyl-1H-imidazol-5-yl)-N-[4-[4-(methylsulfonyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 862682-35-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[2-ethyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-[4-(methylsulfonyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 862682-37-9 CAPLUS
 CN 2-Pyrimidinamine, 4-[2-(methoxymethyl)-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-[4-(methylsulfonyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 862682-39-1 CAPLUS
 CN 2-Pyrimidinamine, 4-(1-ethyl-2-propyl-1H-imidazol-5-yl)-N-[4-[4-(methylsulfonyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 862682-41-5 CAPLUS
 CN 2-Pyrimidinamine, 4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-N-[4-[4-(methylsulfonyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 862682-43-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[2-methyl-1-(2-methylpropyl)-1H-imidazol-5-yl]-N-[4-[4-(methylsulfonyl)-1-piperazinyl]phenyl]- (CA INDEX NAME)




RN 862682-45-9 CAPLUS
 CN Ethanone, 1-[4-[4-[2-ethyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinylamino]phenyl]-1-piperazinyl- (CA INDEX NAME)




RN 862682-47-1 CAPLUS
 CN Ethanone, 1-[4-[4-[(4-(1-ethyl-2-propyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 862682-49-3 CAPLUS
 CN Ethanone, 1-[4-[4-[(4-(1-cyclobutyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 862682-51-7 CAPLUS
 CN Ethanone, 1-[4-[4-[(4-(1,2-diethyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 862682-53-9 CAPLUS
 CN Ethanone, 1-[4-[4-[(4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 862682-55-1 CAPLUS
 CN Ethanone, 1-[4-[4-[2-(methoxymethyl)-1-(methyl ethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 862682-57-3 CAPLUS
 CN Ethanone, 1-[4-[4-[4-[2-methyl-1-(2-methylpropyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 862682-61-9 CAPLUS
 CN Ethanone, 1-[4-[4-[4-[1-(cyclopropylmethyl)-2-methyl-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 862682-67-5 CAPLUS
 CN Ethanone, 2-hydroxy-1-[4-[4-[4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)



RN 862682-69-7 CAPLUS
 CN Ethanone, 2-(dimethylamino)-1-[4-[4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 862682-73-3 CAPLUS
 CN Ethanone, 2-(1-azetidinyl)-1-[4-[4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-1-piperazinyl]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 862682-75-5 CAPLUS
 CN Ethanone, 1-[4-[4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-1-piperazinyl]-2-(1-pyrrolidinyl)-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 862682-77-7 CAPLUS
 CN Ethanone, 1-[4-[4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-(4-morpholinyl)-, hydrochloride (1:?) (CA INDEX NAME)



● x HCl


RN 862682-79-9 CAPLUS
 CN Ethanone, 2-(diethylamino)-1-[4-[4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 862682-83-5 CAPLUS
 CN 2-Pyrimidinamine, N-[4-[4-[(2-(dimethylamino)ethyl)sulfonyl]-1-


piperazinyl]phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 862682-85-7 CAPLUS
 CN 2-Pyrimidinamine, N-[4-[4-[(2-methoxyethyl)sulfonyl]-1-piperazinyl]phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)



RN 862682-87-9 CAPLUS
 CN Ethanol, 2-[(4-[4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinylamino]phenyl]-1-piperazinyl)sulfonyl]- (CA INDEX NAME)




RN 862682-95-9 CAPLUS
 CN Ethanone, 1-[4-[4-[(5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinylamino]phenyl]-1-piperazinyl]-2-hydroxy- (CA INDEX NAME)



RN 862682-97-1 CAPLUS


CN 1-Propanone, 1-[4-[4-[(5-chloro-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-1-piperazinyl]-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 862682-99-3 CAPLUS


CN 1-Propanone, 1-[4-[4-[(5-chloro-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-1-piperazinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 862683-01-0 CAPLUS
 CN 1-Propanone, 1-[4-[4-[(5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862683-03-2 CAPLUS
 CN Ethanone, 1-[4-[4-[(5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-methoxy- (CA INDEX NAME)




RN 862683-05-4 CAPLUS
 CN Methanone, [4-[4-[(5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl](1-hydroxycyclopropyl)- (CA INDEX NAME)




RN 862683-07-6 CAPLUS
 CN 1-Propanone, 1-[4-[4-[(5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-methoxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 862683-09-8 CAPLUS
 CN 1-Propanone, 1-[4-[4-[(5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-methoxy-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862683-11-2 CAPLUS


CN 1-Butanone, 1-[4-[4-[(5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 862683-13-4 CAPLUS

CN 1-Propanone, 1-[4-[4-[(5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)




RN 862683-15-6 CAPLUS
 CN Methanone, [4-[4-[(5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]cyclopropyl- (CA INDEX NAME)




RN 862683-17-8 CAPLUS
 CN 1-[4-[4-[(5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862683-19-0 CAPLUS
 CN 1-Propanone, 1-[4-[5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-3-methoxy- (CA INDEX NAME)




RN 862683-21-4 CAPLUS
 CN Cyclopropanecarbonitrile, 1-[4-[4-[5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)



RN 862683-23-6 CAPLUS
 CN Methanone, [4-[4-[5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl][(2R)-tetrahydro-2-furanyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862683-25-8 CAPLUS


CN Methanone, [4-[4-[[5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl][(2S)-tetrahydro-2-furanyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862683-27-0 CAPLUS

CN 1-Butanone, 1-[4-[[5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-3-hydroxy-3-methyl- (CA INDEX NAME)



RN 862683-29-2 CAPLUS


CN 1-Propanone, 1-[4-[[5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-(hydroxymethyl)-2-methyl- (CA INDEX NAME)



RN 862683-31-6 CAPLUS

CN 1-Butanone, 1-[4-[4-[[5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-hydroxy-3-methyl-, (2R)-
(CA INDEX NAME)


Absolute stereochemistry.



RN 862683-33-8 CAPLUS


CN 1-Butanone, 1-[4-[4-[[5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-hydroxy-3-methyl-, (2S)-
(CA INDEX NAME)

Absolute stereochemistry.




RN 862683-35-0 CAPLUS

CN Ethanone, 1-[4-[4-[[5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-(2-propyn-1-yloxy)-
(CA INDEX NAME)




RN 862683-37-2 CAPLUS

CN Methanone, [4-[4-[(5-chloro-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-1-piperazinyl](tetrahydro-3-furanyl)- (CA INDEX NAME)




RN 862683-39-4 CAPLUS

CN 1-Propanone, 1-[4-[4-[(5-chloro-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-1-piperazinyl]-3-(dimethylamino)- (CA INDEX NAME)




RN 862683-41-8 CAPLUS

CN Ethanone, 1-[4-[4-[(5-chloro-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-1-piperazinyl]-2-[(hydroxymethyl)methylamino]- (CA INDEX NAME)




RN 862683-43-0 CAPLUS

CN 1-Propanone, 1-[4-[(5-chloro-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino)phenyl]-1-piperazinyl]-3-hydroxy-2-(hydroxymethyl)- (CA INDEX NAME)




RN 862683-45-2 CAPLUS

CN Ethanone, 1-[4-[(5-chloro-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino)phenyl]-1-piperazinyl]-2-(1H-tetrazol-1-yl)- (CA INDEX NAME)




RN 862683-47-4 CAPLUS

CN Ethanone, 1-[4-[(5-chloro-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino)phenyl]-1-piperazinyl]-2-(2H-tetrazol-5-yl)- (CA INDEX NAME)




RN 862683-49-6 CAPLUS
 CN Methanone, [4-[4-[(5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl][(2S)-1-methyl-2-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862683-51-0 CAPLUS
 CN Ethanone, 1-[4-[4-[(5-chloro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-(methylsulfonyl)- (CA INDEX NAME)




RN 862683-53-2 CAPLUS
 CN 1-Propanone, 2-hydroxy-1-[4-[4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 862683-55-4 CAPLUS

CN Methanone, cyclopropyl[4-[4-[(4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)



RN 862683-57-6 CAPLUS


CN Ethanone, 2-methoxy-1-[4-[4-[(4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)



RN 862683-59-8 CAPLUS

CN 1-Propanone, 2-methoxy-1-[4-[4-[(4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862683-61-2 CAPLUS

CN 1-Propanone, 2-hydroxy-1-[4-[4-[(4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 862683-63-4 CAPLUS

CN 1-Propanone, 2-methoxy-1-[4-[4-[(4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862683-65-6 CAPLUS

CN 1-Propanone, 2-methyl-1-[4-[4-[(4-[(2-methyl-1-(1-methylethyl)-1*H*-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)

RN 862683-67-8 CAPLUS


CN 1-Butanone, 3-hydroxy-3-methyl-1-[4-[4-[(4-[(2-methyl-1-(1-methylethyl)-1*H*-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)

RN 862683-69-0 CAPLUS

CN Methanone, [4-[4-[(4-[(2-methyl-1-(1-methylethyl)-1*H*-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl][(2*R*)-tetrahydro-2-furanyl]- (CA INDEX NAME)

INDEX NAME)


Absolute stereochemistry.



BN 862683-71-4 CAPLUS


CN Methanone, [4-[4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-1-piperazinyl][(2S)-tetrahydro-2-furanyl]-(CA INDEX NAME)

Absolute stereochemistry.



RN 862683-73-6 CAPLUS


CN Methanone, (1-hydroxycyclopropyl)[4-[4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)



BN 862683-75-8 CAPLUS

CN 1-Butanone, 2-hydroxy-1-[4-[4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862683-77-0 CAPLUS


CN 1-Butanone, 2-hydroxy-1-[4-[4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]2-pyrimidinyl]amino]phenyl]-1-piperazinyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 862683-79-2 CAPLUS


CN Cyclopropanecarbonitrile, 1-[[4-[4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]2-pyrimidinyl]amino]phenyl]-1-piperazinyl]carbonyl- (CA INDEX NAME)



RN 862683-81-6 CAPLUS

CN 1-Butanone, 2-hydroxy-3-methyl-1-[4-[(4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino)phenyl]-1-piperazinyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 862683-83-8 CAPLUS

CN 1-Butanone, 2-hydroxy-3-methyl-1-[4-[(4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino)phenyl]-1-piperazinyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 862683-85-0 CAPLUS
 CN 1-Propanone, 3-methoxy-1-[4-[4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 862683-87-2 CAPLUS
 CN 1-Propanone, 3-hydroxy-2,2-dimethyl-1-[4-[4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 862683-89-4 CAPLUS
 CN Ethanone, 2,2-difluoro-1-[4-[4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 862683-91-8 CAPLUS
 CN Ethanone, 1-[4-[4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl-2-(2-propyn-1-yloxy)- (CA INDEX NAME)




RN 862683-93-0 CAPLUS
 CN 1-Propanone, 2-hydroxy-2-methyl-1-[4-[4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl- (CA INDEX NAME)




RN 862683-95-2 CAPLUS
 CN 1-Propanone, 1-[4-[4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl- (CA INDEX NAME)




RN 862684-01-3 CAPLUS
 CN 1-Propanone, 1-[4-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl- (CA INDEX NAME)



RN 862684-03-5 CAPLUS
 CN 1-Propanone, 1-[4-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-1-piperazinyl-3-hydroxy- (CA INDEX NAME)




RN 862684-05-7 CAPLUS
 CN 1-Propanone, 1-[4-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-1-piperazinyl-3-methoxy- (CA INDEX NAME)




RN 862684-07-9 CAPLUS

CN Ethanone, 1-[4-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-methoxy- (CA INDEX NAME)



RN 862684-09-1 CAPLUS


CN 1-Propanone, 1-[4-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-methyl- (CA INDEX NAME)



RN 862684-11-5 CAPLUS


CN 1-Propanone, 1-[4-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-hydroxy-, (2*R*)- (CA INDEX NAME)

Absolute stereochemistry.



RN 862684-13-7 CAPLUS


CN 1-Propanone, 1-[4-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-hydroxy-2-methyl- (CA INDEX NAME)



RN 862684-15-9 CAPLUS

CN 1-Propanone, 1-[4-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862684-17-1 CAPLUS

CN 1-Butanone, 1-[4-[4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl-2-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862684-19-3 CAPLUS

CN 1-Propanone, 1-[4-[4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl-2-methoxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862684-21-7 CAPLUS

CN 1-Butanone, 1-[4-[4-[(5-fluoro-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-hydroxy-3-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862684-23-9 CAPLUS

CN 1-Butanone, 1-[4-[4-[(5-fluoro-4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862684-25-1 CAPLUS

CN 1-Propanone, 1-[4-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-methoxy-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862684-27-3 CAPLUS


CN 1-Butanone, 1-[4-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-hydroxy-3-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




BN 862684-29-5 CAPLUS

CN Ethanone, 2-(acetyloxy)-1-[4-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 862684-31-9 CAPLUS

CN Ethanone, 1-[4-[4-([5-fluoro-4-[2-methyl-1-(methyl ethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino)phenyl]-1-piperazinyl]-2-hydroxy-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 862684-37-5 CAPLUS
 CN Ethanone, 1-[4-[4-[4-(1-cyclobutyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidinyl]amino]phenyl]-1-piperazinyl-2-hydroxy- (CA INDEX NAME)




RN 862684-39-7 CAPLUS
 CN 1-Propanone, 1-[4-[4-[4-(1-cyclobutyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidinyl]amino]phenyl]-1-piperazinyl-2-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 862684-41-1 CAPLUS
 CN 1-Propanone, 1-[4-[(4-(1-cyclobutyl-2-methyl-1H-imidazol-5-yl)-5-fluoro-2-pyrimidinyl)amino]phenyl]-1-piperazinyl-2-hydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 862684-43-3 CAPLUS
 CN Ethanone, 1-[4-[(4-(1-cyclobutyl-2-methyl-1H-imidazol-5-yl)-5-fluoro-2-pyrimidinyl)amino]phenyl]-1-piperazinyl-2-methoxy- (CA INDEX NAME)




RN 862684-45-5 CAPLUS
 CN 2-Pyrimidinamine, 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 862684-49-9 CAPLUS
 CN 2-Pyrimidinamine, 5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 862684-51-3 CAPLUS
 CN 2-Pyrimidinamine, 4-(1-cyclobutyl-2-methyl-1H-imidazol-5-yl)-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 862684-53-5 CAPLUS
 CN 2-Pyrimidinamine, 4-(1-cyclobutyl-2-methyl-1H-imidazol-5-yl)-5-fluoro-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 862684-61-5 CAPLUS
 CN Ethanone, 1-[4-[2-methyl-4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)



RN 862684-65-9 CAPLUS
 CN Ethanone, 1-[4-[2-fluoro-4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-1-piperazinyl]- (CA INDEX NAME)




RN 862684-69-3 CAPLUS
 CN 2-Pyrimidinamine, 5-fluoro-N-[3-fluoro-4-(1-piperazinyl)phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 862684-71-7 CAPLUS
 CN 1-Propanone, 1-[4-[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinylamino]-2-methylphenyl]-1-piperazinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862684-73-9 CAPLUS
 CN Ethanone, 1-[4-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]-2-methylphenyl]-1-piperazinyl]-2-hydroxy- (CA INDEX NAME)




RN 862684-75-1 CAPLUS
 CN Ethanone, 1-[4-[2-fluoro-4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-hydroxy- (CA INDEX NAME)




RN 862684-77-3 CAPLUS
 CN 1-Propanone, 1-[4-[2-fluoro-4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 862684-79-5 CAPLUS
 CN Ethanone, 1-[4-[2-fluoro-4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-methoxy- (CA INDEX NAME)




RN 862684-81-9 CAPLUS
 CN Ethanone, 1-[(2R,6S)-4-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-2,6-dimethyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862684-83-1 CAPLUS
 CN Ethanone, 1-[(2R,5S)-4-[4-[(5-fluoro-4-{2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-2,5-dimethyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862684-87-5 CAPLUS
 CN Ethanone, 1-[4-[2-chloro-4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-hydroxy- (CA INDEX NAME)




RN 862684-91-1 CAPLUS
 CN Ethanone, 1-[4-[2-chloro-4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-hydroxy- (CA INDEX NAME)




RN 862684-93-3 CAPLUS
 CN 1-Propanone, 1-[4-[2-chloro-4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-1-piperazinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.




RN 862684-95-5 CAPLUS
 CN Ethanone, 1-[4-[2-chloro-4-([5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino)phenyl]-1-piperazinyl]-2-methoxy- (CA INDEX NAME)




RN 862685-05-0 CAPLUS
 CN Acetamide, N-[1-[4-([5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino)phenyl]-3-azetidinyl]-2-hydroxy- (CA INDEX NAME)




RN 862685-07-2 CAPLUS
 CN Acetamide, N-[1-[4-([5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino)phenyl]-3-azetidinyl]- (CA INDEX NAME)




RN 862685-09-4 CAPLUS
 CN Methanesulfonamide, N-[1-[4-([5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino)phenyl]-3-azetidinyl]- (CA INDEX NAME)




RN 862685-11-8 CAPLUS
 CN 2-Pyrimidinamine, N-[3-chloro-4-(4-morpholinyl)phenyl]-4-(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl)- (CA INDEX NAME)



RN 862685-13-0 CAPLUS
 CN 2-Pyrimidinamine, N-[3-chloro-4-(4-morpholinyl)phenyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)




RN 862685-15-2 CAPLUS
 CN 2-Pyrimidinamine, N-[4-(2,6-dimethyl-4-morpholinyl)phenyl]-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)



RN 862685-17-4 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-cyclopropyl-1-[4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 862685-19-6 CAPLUS

CN 2-Pyrimidinamine, N-[3-fluoro-4-(4-morpholinyl)phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)



RN 862685-21-0 CAPLUS


CN 2-Pyrimidinamine, 5-fluoro-N-[3-fluoro-4-(4-morpholinyl)phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]- (CA INDEX NAME)



RN 862685-23-2 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-cyclopropyl-1-[4-[(5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 862685-31-2 CAPLUS
 CN Propanamide, N-[(3S)-1-[4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-3-pyrrolidinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 862685-33-4 CAPLUS
 CN Acetamide, N-[(3S)-1-[4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-3-pyrrolidinyl]-2-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 862685-36-7 CAPLUS
 CN Propanamide, N-[(3R)-1-[4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-3-pyrrolidinyl]-2-hydroxy-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862685-38-9 CAPLUS

CN Acetamide, N-[(3R)-1-[4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]2-pyrimidinyl]amino]phenyl]-3-pyrrolidinyl]-2-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 862685-40-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]2-pyrimidinyl]amino]phenyl]-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862685-42-5 CAPLUS

CN 2-Pyrrolidinecarboxamide, 1-[4-[[5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]2-pyrimidinyl]amino]phenyl]-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862685-44-7 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-methyl-1-[4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl]amino]phenyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862685-46-9 CAPLUS

CN Acetamide, N-[(3R)-1-[(4-[(2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)aminophenyl]-3-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862685-48-1 CAPLUS


CN Acetamide, N-[(3R)-1-[3-fluoro-4-[(4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-2-pyrimidinyl)amino]phenyl]-3-pyrrolidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 862771-40-2 CAPLUS

CN 2-Pyrimidinamine, 4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-5-fluoro-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:395300 CAPLUS
 DN 142:430277
 TI Novel imidazole derivatives, their preparation and use as anticancer agents
 IN Honold, Konrad; Scheiblich, Stefan; Von Hirschheydt, Thomas; Voss, Edgar
 PA F. Hoffmann-La Roche A.-G., Switz.
 SO PCT Int. Appl., 56 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040154	A1	20050506	WO 2004-EP11598	20041015
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JE, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050113342	A1	20050526	US 2004-961907	20041012
	US 7169781	B2	20070130		
	AU 2004283845	A1	20050506	AU 2004-283845	20041015
	CA 2538134	A1	20050506	CA 2004-2538134	20041015
	EP 1676163	A1	20060712	EP 2004-765966	20041015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1867563	A	20061122	CN 2004-80030583	20041015
	BR 2004015525	A	20061226	BR 2004-15525	20041015
	JP 2007508344	T	20070405	JP 2006-534696	20041015
	MX 2006PA03698	A	20060605	MX 2006-PA3698	20060331
	KR 2006063985	A	20060612	KR 2006-707335	20060417
	KR 796971	B1	20080122		
	IN 2006CN01307	A	20070629	IN 2006-CN1307	20060417
PRAI	EP 2003-23677	A	20031017		
	WO 2004-EP11598	W	20041015		
OS	CASREACT 142:430277; MARPAT 142:430277				
AB	The invention relates to a group of novel imidazole derivs. I, which are inhibitors of tyrosine kinases. In compds. I, K and L are independently selected from H, halo, alkyl, OH, and alkoxy; X is H, OH, alkoxy, mercapto, alkylthio, etc.; Y is (un)substituted aryl or heteroaryl; Z is halo, OH, alkoxy, allyloxy, alkyl, methylthio, etc.; and n is 1 or 2. The invention also relates to the preparation of I, pharmaceutical compns. containing one or more compds. I as active ingredients, as well as to the use of the compns. for the treatment of disorders mediated by c-met or src tyrosine kinases, such as cancer. II, formed by the substitution of the Weinreb-amide of 3-chlorobenzoyl chloride with lithiated 4-methyl-2-(methylthio)pyrimidine, was converted to the α -keto oxime with nitrite. The oxime underwent cyclization with III (prepared by silylation of 3,5-dichlorobenzyl alc. followed by formylation and				

desilylation) in the presence of NH₄OAc to form N-hydroxyimidazole IV. IV was reduced to give the corresponding NH-imidazole and then oxidized to convert the methylthio group into a methylsulfonyl group, which then underwent substitution with 4-[2-(diethylamino)ethoxy]aniline to give imidazole V. The compds. of the invention are inhibitors of src and C-met tyrosine kinases, and compound V has IC₅₀ values of 0.5 nM and 4 nM, resp.


IT 850919-00-5P, 2-(2,6-Dichlorophenyl)-4-(3-chlorophenyl)-5-[2-[4-(4-morpholino)phenylamino]pyrimidin-4-yl]-imidazole 850919-08-3P,
2-(2,6-Dichlorophenyl)-4-(4-chlorophenyl)-5-[2-[4-(4-morpholino)phenylamino]pyrimidin-4-yl]-imidazole

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazole derivs. and their use as anticancer agents)

RN 850919-00-5 CAPLUS


CN 2-Pyrimidinamine, 4-[4-(3-chlorophenyl)-2-(2,6-dichlorophenyl)-1H-imidazol-5-yl]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



[R5 and R6 in the claims is not "aryl" or phenyl]

RN 850919-08-3 CAPLUS

CN 2-Pyrimidinamine, 4-[4-(4-chlorophenyl)-2-(2,6-dichlorophenyl)-1H-imidazol-5-yl]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1999:425754 CAPLUS
 DN 131:73651
 TI Heteroaryl-substituted imidazoles and their pharmaceutical compositions and uses

IN Gallagher, Timothy Francis; Boehm, Jeffrey Charles; Adams, Jerry Leroy
 PA SmithKline Beecham Corporation, USA
 SO PCT Int. Appl., 74 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932121	A1	19990701	WO 1998-US26862	19981217
	W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2314980	A1	19990701	CA 1998-2314980	19981217
	AU 9919246	A	19990712	AU 1999-19246	19981217
	EP 1037639	A1	20000927	EP 1998-964041	19981217
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
	JP 2001526230	T	20011218	JP 2000-525112	19981217
	ZA 9811631	A	19990621	ZA 1998-11631	19981218
	US 6335340	B1	20020101	US 2000-581842	20000616
	US 20020198206	A1	20021226	US 2002-919251	20020610
	US 6730683	B2	20040504		
PRAI	US 1997-68393P	P	19971219		
	WO 1998-US26862	W	19981217		
	US 2000-581842	A3	20000616		
OS	MARPAT 131:73651				
AB	1,4,5-Substituted imidazoles wherein one of the substituents can be a substituted pyrimidine, pyridazine, or 1,2,4-triazine were prepared for treatment of cytokine mediated diseases by inhibiting the production of IL-1 (interleukin-1), IL-8 (interleukin-8), and TNF (tumor necrosis factor). Thus, I was prepared from Na 2-(methylthio)-4-pyrimidinecarboxaldehyde di-Me acetal via a series of resin-bound intermediates. Cytokine-inhibiting effects of the title compds. were determined in several in vitro and in vivo assays, e.g., a cytokine specific binding protein assay and a TNF- α in traumatic brain injury assay.				
IT	228551-24-4P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)				
	(heteroaryl-substituted imidazoles and their cytokine-inhibiting effects)				
RN	228551-24-4 CAPLUS				
CN	2-Pyrimidinamine, 4-[1,4-bis(4-fluorophenyl)-1H-imidazol-5-yl]-N-[2-(4-morpholinyl)phenyl]- (CA INDEX NAME)				



Two differences
- point of attachment of morpholine
- R6 is not aryl in the claims

RE.CNT 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/586,954

=> log y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	22.28	204.99
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-3.20	-3.20

STN INTERNATIONAL LOGOFF AT 20:00:41 ON 20 DEC 2008